default author photo

Peter Van Vlasselaer

ARMO BioSciences

Redwood City, CA

United States

SCHOLARLY PAPERS

1

DOWNLOADS

148

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Pegilodecakin Combined with Anti-PD-1 Monoclonal Antibodies for Patients with Advanced Renal Cell Carcinoma (IVY): A Multicentre, Open-Label, Phase 1b Trial

Number of pages: 35 Posted: 05 Mar 2019
University of Texas at Houston - Investigational Cancer Therapeutics, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, University of California, Los Angeles (UCLA), University of California, San Francisco (UCSF), University of Texas at Houston - MD Anderson Cancer Center, START Center for Cancer Care, Memorial Sloan Kettering Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, University of California, Los Angeles (UCLA), University of Texas at Houston - Department of Leukemia, ARMO BioSciences, ARMO BioSciences, ARMO BioSciences, ARMO BioSciences, ARMO BioSciences, Eli Lilly and Company, Ltd - Eli Lilly and Company, NYC, ARMO BioSciences and University of Texas at Houston - Department of Genitourinary Medical Oncology
Downloads 148 (500,001)

Abstract:

Loading...

Renal cancer, Pegilodecakin, Nivolumab, Pembrolizumab, phase 1, IL-10, pegylated IL-10